4.7 Article

Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy

Journal

NEUROLOGY
Volume 78, Issue 22, Pages 1714-1720

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182556c05

Keywords

-

Funding

  1. NCI Cancer Center [P30 CA91842]
  2. ICTS/CTSA from the National Center for Research Resources (NCRR), a component of the NIH [UL1RR024992]
  3. NIH Roadmap for Medical Research
  4. Washington University
  5. BJC Institute for Clinical and Translational Sciences
  6. Children's Discovery Institute
  7. NIH [NS055980, NS069669, NS075094, GM47434, HD40182, U54NS065712-02]
  8. Neuroscience Blueprint Core Grant [NS057105]
  9. Hope Center for Neurological Disorders
  10. Muscular Dystrophy Association
  11. Charcot-Marie-Tooth Association
  12. Columbia University Motor Neuron Center
  13. Burroughs Wellcome Fund
  14. Genzyme
  15. Insmed
  16. Knopp
  17. Prosensa
  18. ISIS
  19. Sanofi
  20. MRC [G0601943] Funding Source: UKRI
  21. Medical Research Council [G0601943] Funding Source: researchfish
  22. Muscular Dystrophy UK [RA4/924, RA4/0924] Funding Source: researchfish
  23. Rosetrees Trust [M145] Funding Source: researchfish

Ask authors/readers for more resources

Objective: To identify the gene responsible for 14q32-linked dominant spinal muscular atrophy with lower extremity predominance (SMA-LED, OMIM 158600). Methods: Target exon capture and next generation sequencing was used to analyze the 73 genes in the 14q32 linkage interval in 3 SMA-LED family members. Candidate gene sequencing in additional dominant SMA families used PCR and pooled target capture methods. Patient fibroblasts were biochemically analyzed. Results: Regional exome sequencing of all candidate genes in the 14q32 interval in the original SMA-LED family identified only one missense mutation that segregated with disease state-a mutation in the tail domain of DYNC1H1 (I584L). Sequencing of DYNC1H1 in 32 additional probands with lower extremity predominant SMA found 2 additional heterozygous tail domain mutations (K671E and Y970C), confirming that multiple different mutations in the same domain can cause a similar phenotype. Biochemical analysis of dynein purified from patient-derived fibroblasts demonstrated that the I584L mutation dominantly disrupted dynein complex stability and function. Conclusions: We demonstrate that mutations in the tail domain of the heavy chain of cytoplasmic dynein (DYNC1H1) cause spinal muscular atrophy and provide experimental evidence that a human DYNC1H1 mutation disrupts dynein complex assembly and function. DYNC1H1 mutations were recently found in a family with Charcot-Marie-Tooth disease (type 20) and in a child with mental retardation. Both of these phenotypes show partial overlap with the spinal muscular atrophy patients described here, indicating that dynein dysfunction is associated with a range of phenotypes in humans involving neuronal development and maintenance. Neurology (R) 2012;78:1714-1720

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available